Flag of the European Union EU Clinical Trials Register Help

Clinical trials for CHANGE

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44393   clinical trials with a EudraCT protocol, of which   7405   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    13,577 result(s) found for: CHANGE. Displaying page 665 of 679.
    «« First « Previous 661  662  663  664  665  666  667  668  669  Next» Last»»
    EudraCT Number: 2010-024132-41 Sponsor Protocol Number: BO21223 Start Date*: 2011-06-14
    Sponsor Name: F. Hoffmann-La Roche Ltd.
    Full Title: A MULTICENTER, PHASE III, OPEN-LABEL, RANDOMIZED STUDY IN PREVIOUSLY UNTREATED PATIENTS WITH ADVANCED INDOLENT NON-HODGKIN'S LYMPHOMA EVALUATING THE BENEFIT OF GA101 (RO5072759) PLUS CHEMOTHERAPY C...
    Medical condition: INDOLENT NON-HODGKIN'S LYMPHOMA
    Disease: Version SOC Term Classification Code Term Level
    22.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029547 Non-Hodgkin's lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (GB - no longer in EU/EEA) CZ (Completed) SE (Completed) DE (Completed) HU (Completed) FR (Completed) ES (Completed) IT (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2011-001012-56 Sponsor Protocol Number: I3X-MC-JHTB Start Date*: 2012-08-30
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 2 Study of LY2784544 in Patients with Myeloproliferative Neoplasms
    Medical condition: Myeloproliferative neoplasms (MPNs), myelofibrosis, essential thrombocythemia, and polycythemia vera
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036061 Polycythemia vera LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028537 Myelofibrosis PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015493 Essential thrombocythaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) ES (Ongoing) SE (Completed) AT (Trial now transitioned) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-005431-23 Sponsor Protocol Number: MNA-3521-014-RNDZ Start Date*: 2022-03-31
    Sponsor Name:MiNA Alpha Limited
    Full Title: AN OPEN LABEL, RANDOMISED, PHASE 2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MTL-CEBPA ADMINISTERED IN COMBINATION WITH SORAFENIB OR SORAFENIB ALONE, IN TKI NAÏVE PARTICIPANTS WITH PREVIOUSLY TR...
    Medical condition: Advanced hepatocellular cancer (HCC) as result of hepatitis B and/or hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073071 Hepatocellular carcinoma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036706 Primary liver cancer non-resectable LLT
    20.1 10021881 - Infections and infestations 10008910 Chronic hepatitis B PT
    20.1 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) FR (Completed) BE (Prematurely Ended) SE (Prematurely Ended) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000236-22 Sponsor Protocol Number: Study_protocol_CODEX-P_ver2_1 Start Date*: 2020-12-16
    Sponsor Name:Chronic Obstructive Pulmonary Disease Trial Network (COP:TRIN)
    Full Title: COPD EXacerbation and Pulmonary hypertension Trial - The effect of Sildenafil treatment to patients with COPD exacerbation and pulmonary hypertension
    Medical condition: This study will investigate treatment of patients with chronic obstructive pulmonary disease (COPD), who experience frequent exacerbations (AECOPD). Only patients with a minimum of 2 moderate AECOP...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004854 10019203 Head spinning LLT
    20.1 100000004852 10033405 Pain head LLT
    20.0 100000004852 10019218 Headache NOS LLT
    20.1 100000004856 10000460 Acid dyspepsia LLT
    22.1 100000004856 10013947 Dyspepsia aggravated LLT
    20.0 100000004856 10013948 Dyspepsia and other specified disorders of function of stomach LLT
    21.1 100000004856 10019328 Heartburn-like dyspepsia LLT
    20.1 100000004856 10064536 Functional dyspepsia LLT
    23.1 100000004856 10012727 Diarrhea LLT
    20.0 100000004859 10023222 Joint pain LLT
    21.0 100000004859 10025012 Lumbo-sacral pain LLT
    21.1 100000004859 10028322 Muscle pain LLT
    20.0 100000004856 10033394 Pain epigastric LLT
    21.1 100000004866 10016046 Facial flushing LLT
    20.0 100000004853 10013614 Double vision LLT
    21.0 100000004848 10005604 Blood in urine LLT
    20.0 100000004872 10018801 Gynecomastia LLT
    20.0 100000004872 10060603 Hematospermia LLT
    20.0 100000004851 10002272 Anemia LLT
    22.1 100000004853 10034961 Photophobia aggravated LLT
    20.0 100000004871 10023139 Jaundice NOS LLT
    20.0 100000004853 10030042 Ocular hyperemia LLT
    20.1 100000004853 10051304 Retinal bleeding LLT
    20.1 100000004853 10005889 Blurry vision LLT
    20.1 100000004856 10046272 Upper abdominal pain LLT
    20.0 100000004856 10038263 Reflux oesophagitis LLT
    20.0 100000004856 10047706 Vomiting NOS LLT
    20.0 100000004867 10016558 Fever LLT
    21.1 100000004862 10024969 Lower respiratory tract infection NOS LLT
    20.0 100000004859 10048317 Myalgia aggravated LLT
    21.1 100000004859 10003990 Back pain (without radiation) LLT
    20.1 100000004852 10020922 Hypesthesia LLT
    20.0 100000004852 10027605 Migraine NOS LLT
    21.1 100000004852 10044572 Tremor limb LLT
    20.1 100000004852 10044570 Tremor finger LLT
    20.0 100000004873 10002856 Anxiety attack LLT
    20.0 100000004873 10022442 Insomnia NOS LLT
    20.0 100000004855 10011232 Coughing LLT
    20.0 100000004862 10040756 Sinusitis NOS LLT
    20.0 100000004867 10014210 Edema LLT
    20.0 100000004867 10014211 Edema (NOS) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-001148-67 Sponsor Protocol Number: PB-102-F60 Start Date*: 2018-09-26
    Sponsor Name:Protalix Ltd.
    Full Title: Open Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegunigalsidase Alfa (PRX-102) in Patients With Fabry Disease
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10016016 Fabry's disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NO (Completed) CZ (Completed) ES (Ongoing) SI (Completed) NL (Completed) HU (Completed) IT (Completed) FI (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2019-003301-97 Sponsor Protocol Number: GO41767 Start Date*: 2020-04-15
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB PLUS CARBOPLATIN AND ETOPOSIDE WITH OR WITHOUT TIRAGOLUMAB (ANTI-TIGIT ANTIBODY) IN PATIENTS WITH UNTREATED EXTENSIVE...
    Medical condition: Small cell lung cancer (SCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041067 Small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) PL (Trial now transitioned) AT (Completed) HU (Completed) BE (Completed) ES (Ongoing) GR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: View results
    EudraCT Number: 2010-022710-77 Sponsor Protocol Number: AC-055C301 Start Date*: 2011-06-16
    Sponsor Name:Actelion Pharmaceuticals Ltd
    Full Title: Prospective, randomized, placebo-controlled, double-blind, multicenter, parallel group study to assess the efficacy, safety and tolerability of macitentan in patients with ischemic digital ulcers a...
    Medical condition: Ischemic digital ulcers associated with systemic sclerosis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10028395 - Musculoskeletal and connective tissue disorders 10042953 Systemic sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) CZ (Completed) DK (Prematurely Ended) BG (Completed) FI (Completed) IT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2009-016858-41 Sponsor Protocol Number: E7080-G000-204 Start Date*: 2010-10-05
    Sponsor Name:Eisai Ltd.
    Full Title: An Open-Label, Single-Arm, Multicenter Phase 2 Study of E7080 in Subjects with Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
    Medical condition: Unresectable endometrial cancer and disease progression following platinum-based, first-line chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014740 Endometrial cancer stage III PT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014736 Endometrial cancer recurrent PT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014734 Endometrial cancer metastatic PT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014741 Endometrial cancer stage IV PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) BG (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-014729-18 Sponsor Protocol Number: 5442-012-00 Start Date*: 2009-11-30
    Sponsor Name:Merck & Co., Inc.
    Full Title: “Un Ensayo de Fase IIb, Aleatorizado, Doble Ciego, Controlado con Placebo y Comparador Activo, de Determinación del Rango de Dosis para Evaluar los Efectos de MK-5442 en la Densidad Mineral Ósea ...
    Medical condition: Osteoporosis
    Disease: Version SOC Term Classification Code Term Level
    9 10031285 Osteoporosis postmenopausal LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) GB (Completed) CZ (Completed) DK (Completed) PL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-002415-28 Sponsor Protocol Number: CSL654_3001 Start Date*: 2012-01-19
    Sponsor Name:CSL Behring GmbH
    Full Title: A Phase II/III Open-label, Multicenter, Safety and Efficacy Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein (rIX-FP) in Subjects with Hemophilia B
    Medical condition: Hemophilia B
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004850 10060614 Hemophilia B (Factor IX) LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) AT (Completed) ES (Completed) IT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2010-020053-14 Sponsor Protocol Number: 28431754DIA3015 Start Date*: 2010-09-15
    Sponsor Name:Janssen Research & Development
    Full Title: A Randomized, Double-Blind, Active-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin Versus Sitagliptin in the Treatment of Subjects With Type 2 Diab...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) BE (Completed) NL (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2012-000694-23 Sponsor Protocol Number: PCYC-1112-CA Start Date*: 2012-08-08
    Sponsor Name:Pharmacyclics LLC an Abbvie Company
    Full Title: A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor Ibrutinib versus Ofatumumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia...
    Medical condition: relapsed or refractory CLL/SLL
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10060671 B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IE (Completed) PL (Completed) ES (Completed) IT (Completed) AT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-009995-11 Sponsor Protocol Number: CNIM811B2202 Start Date*: 2009-07-20
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, adaptive-design dose finding study to assess the antiviral efficacy and safety of NIM811 administered in combination with Standard of Care (SOC) for 12 weeks in relapsed HCV-1 infecte...
    Medical condition: Hepatitis C genotype 1 relapser
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019744 Hepatitis C LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) IT (Completed) BE (Completed) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-001460-32 Sponsor Protocol Number: EOP1013B Start Date*: 2006-02-15
    Sponsor Name:Pfizer Inc
    Full Title: A phase 2/3 randomized, controlled, double-masked, multicenter, comparative trial, in parallel groups, to compare the safety and efficacy of intravitreous injections of 0.3 mg pegaptanib sodium ...
    Medical condition: diabetic macular edema
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004853 10057934 Diabetic macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) AT (Completed) DK (Completed) ES (Completed) GB (Completed) PT (Completed) BE (Completed) DE (Completed) GR (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2017-002311-34 Sponsor Protocol Number: MK-3475-672(INCB24360-ECHO-307) Start Date*: 2017-12-12
    Sponsor Name:Incyte Corporation
    Full Title: A Phase 3 Randomized, Double-blind Trial of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB024360) or Placebo in Participants with Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-6...
    Medical condition: Bladder cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10046714 Urothelial carcinoma bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Temporarily Halted) NL (Completed) GB (Completed) PL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-001682-27 Sponsor Protocol Number: GS-US-342-1140 Start Date*: 2014-08-19
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks with Sofosbuvir and Ribavirin for 24 Weeks in Subje...
    Medical condition: Chronic Hepatitis C Virus Infection
    Disease: Version SOC Term Classification Code Term Level
    17.0 10021881 - Infections and infestations 10019744 Hepatitis C PT
    17.0 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-000963-54 Sponsor Protocol Number: FUR-PKPD-05-20 Start Date*: Information not available in EudraCT
    Sponsor Name:Adamed Pharma S.A.
    Full Title: Effectiveness and pharmacokinetic /pharmacodynamic study of Furazidin, prolonged- release tablets, 200 mg in the treatment of patients with uncomplicated lower urinary tract infections (acute or re...
    Medical condition: uncomplicated lower urinary tract infections (acute or recurrent)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10046577 Urinary tract infections HLT
    20.0 10021881 - Infections and infestations 10046571 Urinary tract infection PT
    20.0 10021881 - Infections and infestations 10024981 Lower urinary tract infection LLT
    20.0 10021881 - Infections and infestations 10038140 Recurrent urinary tract infection LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Female
    Trial protocol: PL (Prematurely Ended) DE (Prematurely Ended) HU (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-001491-35 Sponsor Protocol Number: CB103-C-101 Start Date*: 2017-08-11
    Sponsor Name:Cellestia Biotech AG
    Full Title: A Phase I/IIA, Multi-Centre, Open-Label, Dose-Escalation Study with Expansion Arms to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CB-103 Administered Orally in Adu...
    Medical condition: advanced or metastatic solid tumours and haematological malignancies
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10049280 Solid tumour LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066476 Haematological malignancy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) NL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-005007-86 Sponsor Protocol Number: KTE-C19-101 Start Date*: 2016-12-15
    Sponsor Name:Kite Pharma, Inc.
    Full Title: A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE C19 in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL) (ZUMA-1)
    Medical condition: Diffuse Large B-cell Lymphoma (DLBCL), Primary Mediastinal B cell lymphoma (PMBCL) and Transformed Follicular Lymphoma (TFL).
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10036711 Primary mediastinal large B-cell lymphomas HLT
    20.0 100000004851 10012819 Diffuse large B-cell lymphomas HLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing) DE (Completed) FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2020-005559-19 Sponsor Protocol Number: FUR-03-17 Start Date*: 2021-02-23
    Sponsor Name:ADAMED Pharma S.A.
    Full Title: FRUTI - a phase III, randomized, multicenter, double-blind, active control study to evaluate the efficacy and safety of Furazidin prolonged-release tablets, 200 mg compared with Nitrofurantoin prol...
    Medical condition: uncomplicated lower urinary tract infections (acute or recurrent)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10046577 Urinary tract infections HLT
    20.0 10021881 - Infections and infestations 10046571 Urinary tract infection PT
    20.0 10021881 - Infections and infestations 10024981 Lower urinary tract infection LLT
    20.0 10021881 - Infections and infestations 10038140 Recurrent urinary tract infection LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Female
    Trial protocol: PL (Completed) HU (Completed) DE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 661  662  663  664  665  666  667  668  669  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Apr 04 06:46:03 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA